How much is Mallinckrodt stock worth?
One share of MNK stock can currently be purchased for approximately $0.17. How much money does Mallinckrodt make? Mallinckrodt has a market capitalization of $13.96 million and generates $3.16 billion in revenue each year. The company earns $-996.50 million in net income (profit) each year or $8.88 on an earnings per share basis.
What is Mallinckrodt's specialty generics segment?
The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.
What does the company Mallinckrodt do?
Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics.
Where can I buy Mallinckrodt (mnkkq)?
Shares of MNKKQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mallinckrodt's stock price today?
See more
Why is Mallinckrodt stock dropping?
Shares of Mallinckrodt Plc [S: mnk] tumbled 31.2% in trading on Monday after the company said it had filed for Chapter 11 bankruptcy, in part due to a proposed billion-dollar settlement for its alleged role in the U.S. opioid crisis.
Is Mnkkq a good stock to buy?
Our Ai stock analyst implies that there will be a negative trend in the future and the MNKKQ shares are not a good investment for making money. Since this share has a negative outlook we recommend looking for other projects instead to build a portfolio.
What's going on with Mallinckrodt?
The settlement resolves allegations that from January 1, 2013, through June 30, 2020, Mallinckrodt knowingly underpaid Medicaid rebates due for its drug H.P. Acthar Gel (Acthar), in violation of the Federal False Claims Act and the Massachusetts False Claims Act.
Is Mallinckrodt pharmaceuticals still in business?
Mallinckrodt Pharmaceuticals, one of the country's largest opioid producers, filed for bankruptcy in 2020.
Will Mallinckrodt stock go up?
Mallinckrodt Plc quote is equal to 8500.000 USD at 2022-07-19. Based on our forecasts, a long-term increase is expected, the "MNK" stock price prognosis for 2025-10-14 is 8846.340 USD. With a 5-year investment, the revenue is expected to be around +4.07%. Your current $100 investment may be up to $104.07 in 2027.
Why did Mallinckrodt get sued?
Mallinckrodt used deceptive and misleading marketing tactics to encourage use of its highly addictive opioids that harmed communities across the country. Mallinckrodt entered into bankruptcy proceedings shortly after Attorney General James filed a lawsuit against the company in March 2019.
Are they still making oxycodone?
The sale and distribution of generic OxyContin formulations by various manufacturers is being discontinued. Some generic versions of OxyContin Tablets will continue to be avail- able, however we cannot provide an exact timetable for when generic formulations will no longer be available.
Where is Mallinckrodt manufactured?
The generics company, which is expected to be headquartered in St. Louis, Missouri, will have manufacturing sites in St. Louis as well as Greenville, Illinois; Hobart, New York; and Raleigh, North Carolina, in the U.S. It will have sites in Kobe, Sanda and Tokyo, Japan.
How big is Mallinckrodt?
Mallinckrodt Pharmaceuticals spins off from Covidien, becoming an independent, $2 billion public company that develops, manufactures, markets, and distributes specialty pharmaceutical products and diagnostic imaging agents.
Is Mallinckrodt part of Medtronic?
--(BUSINESS WIRE)--Jan. 13, 2014-- Mallinckrodt (NYSE: MNK) announced today that it has entered into a multiyear agreement with Medtronic (NYSE: MDT) to advance availability in the U.S. of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.
Is Mallinckrodt publicly traded?
DUBLIN --(BUSINESS WIRE)--Jul. 1, 2013-- Mallinckrodt plc (NYSE: MNK) begins “regular-way” trading today on the New York Stock Exchange as an independent, global specialty pharmaceuticals company under the symbol MNK.
Who owns Mallinckrodt Pharmaceuticals?
Avon ProductsViewed as an attractive takeover target in the era of leveraged buyouts, Mallinckrodt was bought by Avon Products in 1982 and largely kept intact as a business entity.
Who makes Acthar gel?
Since acquiring Acthar Gel in 2014, Mallinckrodt has made, and continues to make, a significant investment in the drug. For example, the company built on existing data through further studies that evaluated the safety and efficacy of Acthar Gel within our indications.
What pharmacy uses Mallinckrodt Pharmaceuticals?
AccredoMallinckrodt has individual contracts with each of the independent specialty pharmacies in its network, of which Accredo, a specialty pharmacy owned and operated under the Express Scripts umbrella, is one.
How were Mallinckrodt's earnings last quarter?
Mallinckrodt plc (NYSE:MNK) announced its quarterly earnings results on Tuesday, August, 4th. The company reported $1.89 earnings per share for the...
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the following people: Mark C. Trudeau , President, Chief Executive Officer & Director Bryan M. Reasons ,...
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Metacrine (MTCR) , CohBar (CWBR) , Aptevo Therapeutics (APVO) , Integrated BioPharma (I...
What other stocks do shareholders of Mallinckrodt own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Mallinckrodt investors own include Gilead Sciences (GILD)...
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $0.06.
How much money does Mallinckrodt make?
Mallinckrodt (NYSE:MNK) has a market capitalization of $5.16 million and generates $3.16 billion in revenue each year. The company earns $-996.50 m...
How many employees does Mallinckrodt have?
Mallinckrodt employs 3,400 workers across the globe.
What is Mallinckrodt's official website?
The official website for Mallinckrodt is www.mallinckrodt.com .
How has Mallinckrodt's stock performed in 2022?
Mallinckrodt's stock was trading at $0.1250 at the start of the year. Since then, MNKKQ stock has decreased by 44.0% and is now trading at $0.07....
How were Mallinckrodt's earnings last quarter?
Mallinckrodt plc (OTCMKTS:MNKKQ) released its earnings results on Tuesday, May, 3rd. The company reported ($0.95) earnings per share for the quarte...
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the following people: Mr. Mark Christopher Trudeau , Pres, CEO & Director (Age 61, Pay $8.98M) Mr. Hugh...
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Emmaus Life Sciences (EMMA) , Aeterna Zentaris (AEZS) , Abeona Therapeutics (ABEO) , So...
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the OTCMKTS under the ticker symbol "MNKKQ."
How do I buy shares of Mallinckrodt?
Shares of MNKKQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Mallinckrodt's stock price today?
One share of MNKKQ stock can currently be purchased for approximately $0.07.
How much money does Mallinckrodt make?
Mallinckrodt (OTCMKTS:MNKKQ) has a market capitalization of $5.93 million and generates $2.21 billion in revenue each year.
How many employees does Mallinckrodt have?
Mallinckrodt employs 2,800 workers across the globe.
Are investors shorting Mallinckrodt?
When is Mallinckrodt's next earnings date?
Mallinckrodt saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 2,385,600 shares, an increase of 45.2% from the December 31st total of 1,643,500 shares. Based on an average trading volume of 610,400 shares, the days-to-cover ratio is presently 3.9 days. View Mallinckrodt's Short Interest.
Who are some of Mallinckrodt's key competitors?
Mallinckrodt is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022. View our earnings forecast for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Some companies that are related to Mallinckrodt include Biophytis (BPTS), Adial Pharmaceuticals (ADIL), Kala Pharmaceuticals (KALA), Chemomab Therapeutics (CMMB), AcelRx Pharmaceuticals (ACRX), NeuBase Therapeutics (NBSE), Cumberland Pharmaceuticals (CPIX), Cyclerion Therapeutics (CYCN), Aravive (ARAV), Corbus Pharmaceuticals (CRBP), IMARA (IMRA), Rezolute (RZLT), Monopar Therapeutics (MNPR), Gain Therapeutics (GANX) and Vaccinex (VCNX). View all of MNKKQ's competitors..
What is Mallinckrodt's stock price today?
Shares of MNKKQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
How much money does Mallinckrodt make?
One share of MNKKQ stock can currently be purchased for approximately $0.14.
Where are Mallinckrodt's headquarters?
Mallinckrodt has a market capitalization of $11.44 million and generates $2.21 billion in revenue each year. The company earns $-944.60 million in net income (profit) each year or ($7.87) on an earnings per share basis.
